Starling Oncology, Inc. — Form 8-K
Filed August 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Starling Oncology Management LLC (f/k/a TOI Management) entered into a $25M revolving credit facility with Gemino Healthcare Finance LLC (SLR Healthcare ABL) dated August 20, 2026. The facility is secured by a first-priority security interest in medical accounts receivable collateral, carries interest at SOFR + 3.95%, matures August 20, 2029, and includes a $250K commitment fee. Proceeds support working capital and repayment of existing debt.
Why this rating
Routine debt financing for a $137M company; 18% of market cap but standard working capital facility with no material operational or strategic change evident.
See more from August 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.